Semax — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

Semax Peptide Dosing Guide: SubQ, Nasal Spray, Protocol & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Semax Peptide Dosing Guide: Nasal Spray, SubQ, Protocol & Safety (2026) Protocol / Research Dosing Guide Semax Peptide Dosing Guide: Nasal Spray, SubQ, Protocol & Safety (2026) An evidence-based Semax protocol guide covering dosing structure, nasal spray use, cycle length, route considerations, and safety for this ACTH-derived nootropic peptide. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Semax 20mg Vials View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Semax Comparisons Related Protocols Blood Tests FAQ References Semax Quick Start Semax is a synthetic seven-amino-acid peptide (a heptapeptide) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was designed in Russia from a fragment of adrenocorticotropic hormone (ACTH) and a stabilizing Pro-Gly-Pro tail.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (18) · phenotypes (0)

evidence_reference, dosing_reference, safety_reference, mechanism, contraindication_reference, monitoring_reference

Findings (139) · awaiting review (97)

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Semax 20mg Vials View supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Semax Comparisons Related Protocols Blood Tests FAQ References Semax Quick Start Semax is a synthetic seven-amino-acid peptide (a heptapeptide) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro.

safety · pending

In the United States it is not FDA-approved , and as of April 23, 2026 it was removed from FDA's 503A Category 2 list of bulk substances flagged for compounding safety risks because the underlying nominations were withdrawn.

regulatory · pending

It will be discussed at the FDA Pharmacy Compounding Advisory Committee meeting on July 24, 2026 for possible inclusion on the 503A Bulks List for cerebral ischemia and trigeminal neuralgia .

dosing · pending

Subcutaneous injection from a reconstituted vial is also discussed in research planning.

dosing · pending

Schedule Daily administration is typical in research protocols, often divided into morning and afternoon doses to avoid late-day stimulation.

dosing · pending

Measure (injectable) This guide assumes 20 mg lyophilized vials for injectable Semax math, requiring reconstitution with bacteriostatic water before subcutaneous research use.

regulatory · pending

Research status Not FDA-approved.

regulatory · pending

Semax is not FDA-approved in the United States.

regulatory · pending

Removal from FDA Category 2 does not authorize compounding or human use.

dosing · pending

Semax Dosing Protocol & Schedule Semax research planning splits cleanly by route.

dosing · pending

Subcutaneous injection from a reconstituted research vial is less common in studies but is what most US-side research-use vials are sold for.

dosing · pending

The dose ranges below come from the published clinical literature in the corresponding routes — they are reported here as trial-context ranges , not as a dosing recommendation.

dosing · pending

Semax Dosing Guide Choose the format you are researching to see route-specific notes.

dosing · pending

Subcutaneous Injection Intranasal Solution Less common in published research; relevant for those reconstituting a research-use lyophilized vial.

dosing · pending

Subcutaneous Semax is much less common in the published literature than the intranasal route.

dosing · pending

The injectable math on this page assumes a 20 mg lyophilized research vial intended for reconstitution and subcutaneous research administration.

dosing · pending

Russian clinical references and review summaries describe injectable Semax in research contexts at amounts up to about 1 mg per kilogram of body weight in some animal pharmacology models, but human subcutaneous research data is sparse.

dosing · pending

Reported injectable Semax research ranges (trial-context only) Context Animal pharmacology (rodent) Reported amount Up to ~1 mg/kg Notes Not human-applicable; for context only Source type Animal pharmacology summaries Context Human research-community planning (subQ) Reported amount Sub-milligram per administration Notes Sparse direct human data Source type Community research planning, not formal trials Context Reported amount Notes Source type Animal pharmacology (rodent) Up to ~1 mg/kg Not human-applicable; for context only Animal pharmacology summaries Human research-community planning (subQ) Sub-milligram per administration Sparse direct human data Community research planning, not formal trials Injectable subQ Semax has limited human evidence.

dosing · pending

Subcutaneous research-context use exists, but does not have the same depth of published human data.

dosing · pending

Bottles are commonly sold at concentrations such as 0.1% (1 mg/mL) or 1% (10 mg/mL), and the label should specify the amount delivered per spray o

dosing · pending

This is not a dosing recommendation.

dosing · pending

Reported intranasal Semax research ranges (trial-context only) Context Cognitive / nootropic research planning Total daily amount (reported) About 0.6 to 1.5 mg/day Pattern (reported) Split into 2 administrations (morning + early afternoon) Source type Russian clinical literature (Voronina 2023; Kaplan 1996) Context Acute ischemic stroke (clinical, Russia) Total daily amount (reported) Higher daily amounts under hospital supervision Pattern (reported) Multiple daily administrations during acute period Source type Gusev 1997 acute-stroke clinical study Context Healthy-volunteer cognitive-attention study Total daily amount (reported) Single intranasal administration of about 1.2 mg Pattern (reported) One-time research administration Source type ADDF Cognitive Vitality summary Context Total daily amount (reported) Pattern (reported) Source type Cognitive / nootropic research planning About 0.6 to 1.5 mg/day Split into 2 administrations (morning + early afternoon) Russian clinical literature (Voronina 2023; Kaplan 1996) Acute ischem

dosing · pending

ic stroke (clinical, Russia) Higher daily amounts under hospital supervision Multiple daily administrations during acute period Gusev 1997 acute-stroke clinical study Healthy-volunteer cognitive-attention study Single intranasal administration of about 1.2 mg One-time research administration ADDF Cognitive Vitality summary These are reported trial-context ranges and pharmacy summaries, not a dosing recommendation.

safety · pending

Semax Side Effects & Safety Semax safety reporting in accessible English-language literature is thin.

safety · pending

The clearest summary comes from the Alzheimer's Drug Discovery Foundation (2020), which described 'very little human evidence for potential side effects' despite many preclinical trials.

safety · pending

The 2022 Pharmaceutics review on Russian peptide biopharmaceuticals corroborates the low-toxicity framing.

outcome · pending

Cycle Guidelines (research-context) Approach Standard short course Duration 10-14 days Review point End of course Best for Acute clinical research contexts in the literature Approach Extended cognitive course Duration 4-6 weeks Review point Week 4 Best for Cognitive performance research planning Approach Cycled use Duration 4-6 weeks on, 2-4 weeks off Review point End of each cycle Best for Reducing tolerance signals reported in research-community discussions Approach Duration Review point Best for Standard short course 10-14 days End of course Acute clinical research contexts in the literature Extended cognitive course 4-6 weeks Week 4 Cognitive performance research planning Cycled use 4-6 weeks on, 2-4 weeks off End of each cycle Reducing tolerance signals reported in research-community discussions Cycle structures are inferred from Russian clinical practice and community research planning.

dosing · pending

Route boundary Do not move research-context dosing from one route to another.

dosing · pending

A 1.2 mg intranasal amount and a 1.2 mg subcutaneous amount produce very different exposure profiles, and the published literature is not interchangeable across routes.

dosing · pending

Supplies math below is for the subcutaneous research format using a 20 mg lyophilized vial reconstituted with 4 mL bacteriostatic water (final concentration: 5 mg/mL).

dosing · pending

Daily research planning of about 0.5 mg = 0.10 mL = 10 units on a U-100 syringe.

dosing · pending

Verified Supplier Verified Supplier Semax 20mg Vials Copy PEPPAL code View supply Blood Test At-Home Blood Test Rythm Health At-Home Blood Test View Blood Test Injection Supplies Swabs Sterile alcohol pads.

dosing · pending

Peptide Vials (20 mg, subQ research format) One 20 mg vial reconstituted with 4 mL bacteriostatic water yields about 40 daily research administrations of 0.5 mg.

dosing · pending

Insulin Syringes (U-100, 0.3 mL / 30 unit) Smaller-barrel U-100 syringes are easier for sub-half-mL draws.

dosing · pending

Bacteriostatic Water Use 4 mL per 20 mg vial.

dosing · pending

One 10 mL bottle reconstitutes two vials with margin for losses.

dosing · pending

nning note 2-8 weeks 1 x 10 mL bottle 2 weeks: 1 vial uses 4 mL total.; 4 weeks: 1 vial uses 4 mL total.; 6 weeks: 2 vials use 8 mL total.; 8 weeks: 2 vials use 8 mL total; consider a second bottle if you want extra margin.

dosing · pending

2-8 weeks 1 x 10 mL bottle 2 weeks: 1 vial uses 4 mL total.; 4 weeks: 1 vial uses 4 mL total.; 6 weeks: 2 vials use 8 mL total.; 8 weeks: 2 vials use 8 mL total; consider a second bottle if you want extra margin.

Processing

Processed into 31 searchable sections.